SCHEMBL12876324

SCHEMBL12876324

Cc1cccc(-c2csc(CO)n2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.56
ATP4A P20648 2/20 0.56
ATP4B P51164 2/20 0.56
IRAK4 Q9NWZ3 1/20 0.52
TSHR P16473 1/20 0.45
RECQL P46063 1/20 0.45
LTA4H P09960 1/20 0.45
ALDH1A1 P00352 4/20 0.44
RAB9A P51151 3/20 0.44
C1S P09871 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HTR3A P46098 1/20 0.44
PRMT6 Q96LA8 1/20 0.43
MEN1 O00255 3/20 0.43
LMNA P02545 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
LOXL2 Q9Y4K0 1/20 0.43
HSD17B1 P14061 1/20 0.43
HSD17B2 P37059 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12876858 0.84 ATP4A (0.52) SCN9AATP4AATP4BTSHRRECQL
SCHEMBL12876323 0.84 ATP4A (0.52) SCN9AATP4AATP4BTSHRRECQL
SCHEMBL12876330 0.81 ATP4A (0.52) ATP4AATP4BTSHRRECQLLTA4H
SCHEMBL17887342 0.81 ATP4A (0.49) SCN9AATP4AATP4BTSHRRECQL
SCHEMBL2706151 0.80 RAB9A (0.65) IRAK4LTA4HALDH1A1RAB9AL3MBTL1
SCHEMBL1745076 0.80 LOXL2 (0.64) SCN9AATP4AATP4BALDH1A1RAB9A
SCHEMBL8257849 0.78 RECQL (0.70) SCN9AATP4AATP4BTSHRRECQL
SCHEMBL1197815 0.78 SCN9A (0.59) SCN9AIRAK4LTA4HALDH1A1MEN1
SCHEMBL7120830 0.77 ALDH1A1 (0.65) ATP4AATP4BTSHRRECQLLTA4H
SCHEMBL30087395 0.77 ATP4A (0.57) ATP4AATP4BTSHRRECQLLTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A SCN9A 298/4885ATP4A 2758/4885ATP4B 2711/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.